Clinically Important Changes in Acute Pain Outcome Measures

Bromm, 1984, The measurement of pain in man, 13

Turk, 1993, Neglected topics in chronic pain treatment outcome studies, Pain, 53, 3, 10.1016/0304-3959(93)90049-U

Farrar, 2000, Defining the clinically important difference in pain outcome measures, Pain, 88, 287, 10.1016/S0304-3959(00)00339-0

Coluzzi, 2001, Breakthrough cancer pain, Pain, 91, 123, 10.1016/S0304-3959(00)00427-9

Lichtor, 1999, The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain, Anesth Analg, 89, 732, 10.1213/00000539-199909000-00038

Streisand, 1991, Absorption and bioavailability of oral transmucosal fentanyl citrate, Anesthesiology, 75, 223, 10.1097/00000542-199108000-00009

Hanley, 1989, Receiver operating characteristic (ROC) methodology, Crit Rev Diag Imag, 29, 307

Hanley, 1983, A method of comparing the areas under receiver operating characteristic curves derived from the same cases, Radiology, 148, 839, 10.1148/radiology.148.3.6878708

Zeger, 1988, Models for longitudinal data, Biometrics, 44, 1049, 10.2307/2531734

Farrar, 1998, Oral transmucosal fentanyl citrate, J Natl Cancer Inst, 90, 611, 10.1093/jnci/90.8.611

Goldsmith, 1993, Criteria for clinically important changes in outcomes, OMERACT Committee. Rheumatology, 20, 561

Moore, 1996, Deriving dichotomous outcome measures from continuous data in randomized controlled trials of analgesics, Pain, 66, 229, 10.1016/0304-3959(96)03032-1

Sheiner, 1994, A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data, Clin Pharmacol Ther, 56, 309, 10.1038/clpt.1994.142

Max, 1992, Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy, N Engl J Med, 326, 1250, 10.1056/NEJM199205073261904

Leijon, 1989, Central post-stroke pain—a controlled trial of amitriptyline and carbamazepine, Pain, 36, 27, 10.1016/0304-3959(89)90108-5